X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
egfr-tkis (61) 61
oncology (59) 59
index medicus (56) 56
lung cancer (46) 46
epidermal growth factor (39) 39
humans (39) 39
mutation (38) 38
gefitinib (37) 37
acquired-resistance (35) 35
lung cancer, non-small cell (32) 32
respiratory tract diseases (32) 32
tyrosine (31) 31
nsclc (29) 29
lung neoplasms - drug therapy (28) 28
chemotherapy (27) 27
carcinoma, non-small-cell lung - drug therapy (26) 26
kinases (25) 25
non-small cell lung carcinoma (25) 25
erlotinib (24) 24
epidermal growth factor receptors (23) 23
open-label (23) 23
cancer (21) 21
metastasis (20) 20
non-small cell lung cancer (20) 20
resistance (20) 20
cancer therapies (19) 19
protein kinase inhibitors - therapeutic use (19) 19
protein-tyrosine kinase (19) 19
adenocarcinoma (18) 18
neoplasms. tumors. oncology. including cancer and carcinogens (18) 18
tyrosine kinase inhibitors (18) 18
lung neoplasms - genetics (17) 17
care and treatment (16) 16
drug resistance (16) 16
egfr tkis (16) 16
growth-factor receptor (16) 16
carcinoma, non-small-cell lung - genetics (15) 15
expression (15) 15
review (15) 15
1st-line treatment (14) 14
receptor, epidermal growth factor - antagonists & inhibitors (14) 14
apoptosis (13) 13
egfr mutation (13) 13
receptor, epidermal growth factor - genetics (13) 13
analysis (12) 12
animals (12) 12
female (12) 12
genetic aspects (12) 12
male (12) 12
patients (12) 12
cell biology (11) 11
development and progression (11) 11
drug resistance, neoplasm (11) 11
egfr (11) 11
egfr mutations (11) 11
aged (10) 10
carcinoma, non-small-cell lung - pathology (10) 10
cell lung-cancer (10) 10
gefitinib resistance (10) 10
lung neoplasms - pathology (10) 10
medical prognosis (10) 10
middle aged (10) 10
mutations (10) 10
prognosis (10) 10
research (10) 10
small cell lung carcinoma (10) 10
antineoplastic agents - therapeutic use (9) 9
cancer research (9) 9
cell line, tumor (9) 9
epithelial-mesenchymal transition (9) 9
lung cancer, small cell (9) 9
phase-ii (9) 9
proteins (9) 9
respiratory system (9) 9
tumors (9) 9
acquired resistance (8) 8
activation (8) 8
antineoplastic agents - pharmacology (8) 8
cell growth (8) 8
cell proliferation (8) 8
egfr‐tkis (8) 8
erbb receptors - genetics (8) 8
gene expression (8) 8
health aspects (8) 8
medicine & public health (8) 8
phenols (8) 8
protein kinase inhibitors - pharmacology (8) 8
protein-tyrosine kinase receptors (8) 8
studies (8) 8
survival (8) 8
targeted therapy (8) 8
azd9291 (7) 7
biotechnology & applied microbiology (7) 7
brain metastases (7) 7
drug-resistance (7) 7
gene mutations (7) 7
lung adenocarcinoma (7) 7
lung neoplasms - metabolism (7) 7
met amplification (7) 7
oncotargets and therapy (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2015, Volume 5, Issue 5, pp. 390 - 401
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors... 
Resistance | Mechanisms | TKIs | EGFR | TARGETED THERAPY | ACQUIRED-RESISTANCE | T790M MUTATION | GEFITINIB RESISTANCE | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | GROWTH-FACTOR RECEPTOR | ERLOTINIB RESISTANCE | PHARMACOLOGY & PHARMACY | INTEGRIN BETA1 | TUMOR-GROWTH | ALK, anaplastic lymphoma kinase | BH3, BCL2-homology domain 3 | PDGFRs, platelet-derived growth factor receptors | lymphoma-2 | PDGFs, platelet-derived growth factors | PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase,catalytic subunit alpha | VEGFR, vascular endothelial growth factor receptor | RAF, rapidly accelerated fibrosarcoma | FGFs, fibroblast growth factors | BCL-2, B-cell CLL | IGFBPs, IGF-binding proteins | ERK1 | BIM, BCL2-like 11 | ABCC10, ATP binding cassette, sub-family C, member 10 | ABCC1, ATP binding cassette, sub-family C, member 1 | VEGF, vascular endothelial growth factor | TKs, tyrosine kinases | HER, human epidermal receptor | MEK, mitogen-activated protein kinase | EGFR, epidermal growth factor receptor | BRAF, v-RAF murine sarcoma viral oncogene homolog B1 | AXL, Anexelekto | AKT, protein kinase B | IL, interleukin | TKIs, tyrosine kinase inhibitors | RAS, rat sarcoma | RTK, tyrosine kinase receptor | MAPK, mitogen-activated protein kinase | FGFRs, fibroblast growth factor receptors | SOCS3, suppressor of cytokine signaling 3 | EMT, epithelial mesenchymal transition | IGF, insulin growth factor | Review | 2, extracellular signal-regulated kinases | EML4, echinoderm microtubule-associated protein-like 4 | ABCG2, ATP binding cassette, sub-family G, member 2 | ABCB1, ATP binding cassette, sub-family B, member 1 | BCL2L11 | IL-6R, IL-6 receptor | IGF-1R, IGF-1 receptor | SF, scatter factor | PI3K, phosphatidylinositol-3-kinase | CML, chronic myelogenous leukemia | EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors | JAK, janus kinase | NSCLC, non-small cell lung cancer | ABC, ATP binding cassette | GAS6, growth-arrest-specific protein 6 | STAT, signal transducers and activators of transcription | EGFRvIII, EGFR variant III | CRKL, Crk-like protein | HGF, hepatocyte growth factor | PTEN, phosphatase and tensin homolog
Journal Article
by Zhong, WZ and Zhou, Q and Wu, YL
ONCOTARGET, ISSN 1949-2553, 09/2017, Volume 8, Issue 41, pp. 71358 - 71370
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been established as the standard therapy for EGFR-sensitizing mutant advanced... 
EGFR-TKIs resistance mechanism | 1ST-LINE TREATMENT | ACQUIRED-RESISTANCE | PHASE-II | OPEN-LABEL | advanced NSCLC | GEFITINIB RESISTANCE | POTENTIAL MECHANISM | CELL BIOLOGY | EGFR mutation | GROWTH-FACTOR RECEPTOR | MET AMPLIFICATION | T790M MUTATIONS | precision medicine | TYROSINE KINASE INHIBITOR
Journal Article
Lung Cancer, ISSN 0169-5002, 2013, Volume 81, Issue 3, pp. 328 - 336
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 52, pp. 90557 - 90578
Journal Article
ESMO Open, ISSN 2059-7029, 05/2016, Volume 1, Issue 3, p. e000060
Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in... 
EGFR TKIs
Journal Article
Chinese Journal of Cancer Prevention and Treatment, ISSN 1673-5269, 03/2018, Volume 25, Issue 6, pp. 449 - 454
Journal Article
by Li, L and Hu, MD and Wang, T and Chen, HZ and Xu, L
FRONTIERS IN ONCOLOGY, ISSN 2234-943X, 01/2020, Volume 9
Background: The major limitation of targeted cancer therapy is development of acquired resistance. Intratumoral heterogeneity and coexist of multiple... 
targeted therapy | EGFR TKIs | ACTIVATION | CMap | PREVENTION | breast cancer | MECHANISMS | lung cancer | EXPRESSION PATTERNS | EVOLUTION | ONCOLOGY | aspirin | reposition | SUPPRESSES | tamoxifen | Breast cancer
Journal Article
Molecular cancer, ISSN 1476-4598, 11/2019, Volume 18, Issue 1, pp. 165 - 14
The ATLANTIC trial reported that higher PD-L1 expression in tumors was involved in a higher objective response in patients with EGFR /ALK non-small cell lung... 
Signaling pathways | PD-L1 | EGFR-TKIs resistance | Lung cancer | Immunotherapy
Journal Article
Chinese Journal of Lung Cancer, ISSN 1009-3419, 2013, Volume 16, Issue 10, pp. 535 - 540
Journal Article
JOURNAL OF ONCOLOGY, ISSN 1687-8450, 08/2019, Volume 2019, pp. 1 - 11
Immunotherapy has offered a new opportunity for the treatment of many malignancies. In patients with lung cancer, immune checkpoint inhibitors have... 
TGF-BETA | METASTASIS | ONCOLOGY | INFLAMMATION | EGFR-TKIS | RESISTANCE | SUPPRESSOR-CELLS | PROGNOSTIC VALUE | UP-REGULATION | EXPRESSION | CARCINOMA | Care and treatment | Immune response | Lung cancer | Immunotherapy | Development and progression | B cells | Tumors | Cancer
Journal Article
Chinese Journal of Cancer Prevention and Treatment, ISSN 1673-5269, 09/2013, Volume 20, Issue 18, pp. 1450 - 1454
Journal Article
BMC CANCER, ISSN 1471-2407, 04/2019, Volume 19, Issue 1, p. 410
BackgroundSystemic treatment of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the introduction of targeted therapies. The analysis... 
Treatment monitoring | EGFR mutations | NSCLC | MECHANISM | ONCOLOGY | EGFR-TKIs | Digital droplet PCR | ACQUIRED-RESISTANCE | NGS | Circulating tumor DNA | AZD9291 | Case studies | Chemotherapy | Usage | Care and treatment | Gene mutations | Development and progression | Genetic aspects | Research | Lung cancer, Non-small cell | Cancer
Journal Article
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 10/2019, Volume 8, Issue 5, pp. 667 - 667
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell... 
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) | MECHANISM | ONCOLOGY | AXL | RESPIRATORY SYSTEM | IPA-3 | non-small cell lung cancer (NSCLC) | resistance | KINASE-C-IOTA | Auranofin
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.